350 related articles for article (PubMed ID: 28174171)
1. Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease.
Hung SC; Kuo KL; Wu CC; Tarng DC
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28174171
[No Abstract] [Full Text] [Related]
2. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
[TBL] [Abstract][Full Text] [Related]
3. [The uremic toxin, indoxyl sulfate, signifies cardio-renal risk and intestinal-renal relationship].
Kiss I
Orv Hetil; 2011 Oct; 152(43):1724-30. PubMed ID: 21983398
[TBL] [Abstract][Full Text] [Related]
4. Indoxyl sulfate, a valuable biomarker in chronic kidney disease and dialysis.
Tan X; Cao X; Zou J; Shen B; Zhang X; Liu Z; Lv W; Teng J; Ding X
Hemodial Int; 2017 Apr; 21(2):161-167. PubMed ID: 27616754
[TBL] [Abstract][Full Text] [Related]
5. Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease.
Gao H; Liu S
Life Sci; 2017 Sep; 185():23-29. PubMed ID: 28754616
[TBL] [Abstract][Full Text] [Related]
6. Aryl Hydrocarbon Receptor Activation in Chronic Kidney Disease: Role of Uremic Toxins.
Brito JS; Borges NA; Esgalhado M; Magliano DC; Soulage CO; Mafra D
Nephron; 2017; 137(1):1-7. PubMed ID: 28490014
[TBL] [Abstract][Full Text] [Related]
7. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease.
Lin CJ; Liu HL; Pan CF; Chuang CK; Jayakumar T; Wang TJ; Chen HH; Wu CJ
Arch Med Res; 2012 Aug; 43(6):451-6. PubMed ID: 22885091
[TBL] [Abstract][Full Text] [Related]
8. Indoxyl Sulfate, a Uremic Endotheliotoxin.
Lano G; Burtey S; Sallée M
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32260489
[TBL] [Abstract][Full Text] [Related]
9. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease.
Sato E; Mori T; Mishima E; Suzuki A; Sugawara S; Kurasawa N; Saigusa D; Miura D; Morikawa-Ichinose T; Saito R; Oba-Yabana I; Oe Y; Kisu K; Naganuma E; Koizumi K; Mokudai T; Niwano Y; Kudo T; Suzuki C; Takahashi N; Sato H; Abe T; Niwa T; Ito S
Sci Rep; 2016 Nov; 6():36618. PubMed ID: 27830716
[TBL] [Abstract][Full Text] [Related]
10. Impact of Indoxyl Sulfate on Progenitor Cell-Related Neovascularization of Peripheral Arterial Disease and Post-Angioplasty Thrombosis of Dialysis Vascular Access.
Wu CC; Hung SC; Kuo KL; Tarng DC
Toxins (Basel); 2017 Jan; 9(1):. PubMed ID: 28067862
[TBL] [Abstract][Full Text] [Related]
11. Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.
Li DY; Tang WHW
Semin Nephrol; 2018 Mar; 38(2):193-205. PubMed ID: 29602401
[TBL] [Abstract][Full Text] [Related]
12. The harmful effect of indoxyl sulfate on neovascularization in chronic kidney disease.
Dou L; Burtey S
Kidney Int; 2016 Mar; 89(3):532-4. PubMed ID: 26880447
[TBL] [Abstract][Full Text] [Related]
13. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease.
Rossi M; Campbell KL; Johnson DW; Stanton T; Vesey DA; Coombes JS; Weston KS; Hawley CM; McWhinney BC; Ungerer JP; Isbel N
Arch Med Res; 2014 May; 45(4):309-17. PubMed ID: 24751327
[TBL] [Abstract][Full Text] [Related]
14. Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease.
Barisione C; Ghigliotti G; Canepa M; Balbi M; Brunelli C; Ameri P
Curr Drug Targets; 2015; 16(4):366-72. PubMed ID: 25537654
[TBL] [Abstract][Full Text] [Related]
15. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120.
Niwa T
Ther Apher Dial; 2011 Apr; 15(2):120-4. PubMed ID: 21426500
[TBL] [Abstract][Full Text] [Related]
16. New insight into the redox properties of uremic solute indoxyl sulfate as a pro- and anti-oxidant.
Miyamoto Y; Watanabe H; Otagiri M; Maruyama T
Ther Apher Dial; 2011 Apr; 15(2):129-31. PubMed ID: 21426502
[TBL] [Abstract][Full Text] [Related]
17. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease.
Fujii H; Nakai K; Fukagawa M
Ther Apher Dial; 2011 Apr; 15(2):125-8. PubMed ID: 21426501
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 and Free Indoxyl Sulfate Levels Are Associated with miR-126 in Chronic Kidney Disease.
Fourdinier O; Glorieux G; Brigant B; Diouf M; Pletinck A; Vanholder R; Choukroun G; Verbeke F; Massy ZA; Metzinger-Le Meuth V; Metzinger L; Group-EUTox OBOTEUTW
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638892
[TBL] [Abstract][Full Text] [Related]
19. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease.
Ito S; Higuchi Y; Yagi Y; Nishijima F; Yamato H; Ishii H; Osaka M; Yoshida M
J Leukoc Biol; 2013 Jun; 93(6):837-45. PubMed ID: 23362306
[TBL] [Abstract][Full Text] [Related]
20. [Research progress of the uremic toxin indoxyl sulfate in cardiovascular complication of end-stage renal diseases].
Guo CC; Xia WW; Zhang AH
Sheng Li Xue Bao; 2018 Dec; 70(6):657-662. PubMed ID: 30560276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
